HeartIO

HeartIO is a U. S. -based company offering an AI-powered diagnostic platform for heart disease, focusing on early detection through rapid ECG analysis. Their innovative technology enables healthcare providers to assess patients' heart health efficiently.

HeartIO, founded in 2018 and headquartered in Pittsburgh, US, specializes in advancing heart disease diagnostics through its AI platform. The company raised a total of USD 4. 25 mn in seed funding from investors, including Bessel, VU Venture Partners, Intelligence Ventures, LIVEX, and Audacious Capital, with the latest funding round occurring on March 17, 2026. The founder's background details are not available, and there is no information regarding any company pivots or subsidiaries.

HEARTio's core offering is an AI-powered diagnostic platform that utilizes a simple electrocardiogram (ECG) to diagnose heart disease, specifically targeting the early detection of conditions that could lead to heart attacks. The platform enables healthcare providers to instantly assess patients' heart health, leveraging advanced algorithms to analyze ECG data within a span of just 10 seconds. This innovation aims to prevent heart attacks by identifying plaque buildup in the arteries before clinical symptoms arise. The end users of HEARTio's services primarily include healthcare professionals, hospitals, and clinics, particularly within the United States and select European markets, where the demand for non-invasive cardiovascular diagnostics is increasing.

HEARTio generates revenue through partnerships with healthcare providers and institutions that integrate its ECG diagnostic platform into their services. The business model is structured around subscriptions for access to the technology, allowing clients to utilize the AI diagnostics for their patient populations. Given the platform's emphasis on efficiency and accuracy, providers benefit from improved patient outcomes and reduced emergency intervention costs. Specific pricing plans and transaction structures have not been disclosed, but the service is tailored to meet the needs of individual healthcare facilities, enabling them to adopt HEARTio's technology as part of their cardiovascular care offerings.

In March 2026, HeartIO raised USD 4. 25 mn in seed funding to support their strategy for growth, which includes designing new products aimed at enhancing their ECG diagnostics capabilities. The company plans to expand into additional geographic markets, specifically targeting regions within Europe and Asia, with a focus on launching by 2027. The recent funding will enable HeartIO to accelerate its product development and marketing efforts to ensure successful entry into these new markets.